Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine patch for cognitive impairment in multiple sclerosis
NCT00881205Phase 4Terminated
- Sponsor
- Novartis
- Start
- Apr 2009
- Primary completion
- Jan 2011
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rivastigmine in cognitive impairment, sponsored by Novartis. Primary endpoint: Selective Reminding Test Total Recall at 16 weeks. Started Apr 2009; status: terminated.
02
Drugs
rivastigmine
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT00881205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881205.